



1646  
J8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Avi J. ASHKENAZI	Examiner: C. Kaufman
Serial No. 09/896,096	Docket No.: 22338-40100 (P1134R2C2)
Filed: June 28, 2001	Group Art Unit: 1646
For: DcR3 Polypeptide, a TNFR Homolog	

Honorable Commissioner of Patents  
and Trademarks  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

The Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

Attached is a check in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

If Applicant has overlooked the payment of any fees with regard to the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 18-1260.

Respectfully submitted,



Date: December 4, 2003

By: Jeffrey P. Kushan  
Reg. No. 43,401  
Attorney for Applicant

SIDLEY AUSTIN BROWN & WOOD LLP  
1501 K Street, N.W.  
Washington, DC 20005  
202-736-8000

DAS/yea  
Enclosures



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-40100 (P1134R2C2)	Application No. 09/896,096
	Applicant(s): Avi J. Ashkenazi	Examiner: C. Kaufman
	Filing Date: June 28, 2001	Group Art Unit: 1646

### U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		09/518,931	3/3/2000	R. Gentz et al.			
		09/006,352	1/13/1998	R. Gentz et al.			
		60/303,224	7/6/2001	R. Gentz et al.			
		60/252,131	11/21/2000	R. Gentz et al.			
		60/227,598	8/25/2000	R. Gentz et al.			
		60/168,235	12/1/1999	R. Gentz et al.			
		60/146,371	8/2/1999	R. Gentz et al.			
		60/131,964	4/30/1999	R. Gentz et al.			
		60/131,270	4/27/1999	C. Watanabe et al.			
		60/124,092	3/12/1999	R. Gentz et al.			
		60/121,774	3/4/1999	R. Gentz et al.			
		60/035,496	1/14/1997	W. Ying-Fei et al.			

### FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

### OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	Bai et al. "Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster." PNAS, Vol. 97, pp. 1230-1235 (2000).
	Otsuki et al. "Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients." Clinical and Experimental Immunology, Vol. 119, No. 2, pp. 323-327 (2000).

EXAMINER	DATE CONSIDERED
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	
	<b>SHEET 1 OF 1</b>